FGFR3 SV-altered bladder cancers were significantly more likely to be from older patients (P = 4.5 × 10−5; Supplementary Table S3, available at https://doi.org/10.1016/j.esmoop.2022.100641) and less likely to be TMB-high [260/1051, 24.7%, versus 2336/6688, 34.9%; odds ratio = 1.63; P = 3.49 × 10−11; median TMB 6.09 (IQR 3.48-9.57) versus 6.25 (IQR 3.75-12.50); Supplementary Figure S3, available at https://doi.org/10.1016/j.esmoop.2022.100641], versus unaltered samples. This evidence concerns the gene FGFR3 and urinary bladder cancer.